United Therapeutics Announces BREEZE Study of Investigational Tyvaso DPI™ Meets Primary Objective
Study demonstrated safety and tolerability of Tyvaso DPI™ in patients with PAH transitioning from Tyvaso® Inhalation Solution
A separate study in healthy volunteers demonstrated comparable treprostinil exposure between Tyvaso DPI and Tyvaso Inhalation Solution
Tyvaso DPI NDA filing anticipated in April 2021 with priority review
News provided by
Share this article
Share this article
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 28, 2021 /PRNewswire/ United Therapeutics Corporation (Nasdaq: UTHR) announced today that that the BREEZE study of Tyvaso DPI (inhaled treprostinil) met its primary objective of demonstrating safety and tolerability in patients with pulmonary arterial hypertension (PAH) transitioning from Tyvaso (treprostinil) Inhalation Solution. In addition, a pharmacokinetic (PK) study in healthy volunteers demonstrated comparable treprostinil exposure
United Therapeutics Announces New England Journal of Medicine Publication of the INCREASE Study Evaluating Tyvaso® in Pulmonary Hypertension Associated with Interstitial Lung Disease
INCREASE Study is First to Demonstrate a Clear Benefit in Patients with PH-ILD, a Life-threatening Disease with No Currently FDA-Approved Treatments
Company to host a webcast detailing the INCREASE study results on Tuesday, January 19, 2021 at 4:30 p.m. E.T.
News provided by
Share this article
Share this article
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Jan. 13, 2021 /PRNewswire/ United Therapeutics Corporation (Nasdaq: UTHR) today announced that results from the
INCREASE clinical study of Tyvaso
® (treprostinil) Inhalation Solution for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD) have been published online in the